Tsimberidou, Apostolia M.
Kahle, Michael
Vo, Henry Hiep
Baysal, Mehmet A. http://orcid.org/0000-0002-8446-6531
Johnson, Amber
Meric-Bernstam, Funda
Article History
Accepted: 25 September 2023
First Online: 16 October 2023
Competing interests
: The University of Texas MD Anderson Cancer Center receives licensing fees for their Precision Oncology Decision Support (PODS) database from Philips Healthcare, which supports continued development of the PODS system. A.M.T. declares receipt of clinical trial research funding (to The University of Texas MD Anderson Cancer Center) from Agenus, IMMATICS, Novocure, OBI Pharma, Parker Institute for Cancer Immunotherapy, Tachyon, Tempus and Tvardi; fees for consulting or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I and VinceRx; and travel expenses from ASCO, Cancer Care Crossroads, GenomeWeb Conference and Precision Medicine World Conference. F.M.-B. declares research funding (to The University of Texas MD Anderson Cancer Center) from Aileron Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Calithera Biosciences, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm, eFFECTOR Therapeutics, Genentech, Guardant Health, Klus Pharma, Novartis, Puma Biotechnology, Taiho Pharmaceutical and Takeda Pharmaceuticals; consulting or advisory roles for AbbVie, Aduro BioTech, Alkermes, AstraZeneca, Daiichi Sankyo, DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche, Genentech, GT Apeiron Therapeutics, Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini, OrigiMed, PACT Pharma, Parexel, Pfizer, Protai Bio, Samsung Bioepis, Seattle Genetics, Tallac Therapeutics, Tyra Biosciences, Xencor and Zymeworks; honoraria from Chugai Biopharmaceuticals; and other relationships with the European Organization for Research and Treatment of Cancer and European Society for Medical Oncology. The other authors declare no competing interests.